Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 01, 2024 08:00 ET | Source: Peak Bio, Inc.

Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity

Prioritization of Peak’s ADC cancer therapeutic platform technology and Akari’s PAS-nomacopan for Geographic Atrophy, a disabling ophthalmic diseaseAkari Therapeutics announces leadership changes in...
March 05, 2024 08:00 ET | Source: Peak Bio, Inc.

Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit

BOSTON and PLEASANTON, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and...
January 04, 2024 08:00 ET | Source: Peak Bio, Inc.

Peak Bio, Inc. Awarded Patent with Broad Coverage for Thailanstatin-ADC platform technology (PH-1) a Payload with Novel Immunomodulatory Effects that Target RNA Splicing

Pleasanton, CA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Peak Bio, Inc. ("Peak Bio" or the "Company") (OTCQB) PK: PKBO), announced that it was awarded US Patent No. 11,691,982 B2 entitled “Thailanstatin...
September 19, 2023 16:00 ET | Source: Peak Bio, Inc.

Peak Bio, Inc. Announces Filing of Provisional Patent Applications for PH-1, a Novel and Specific Immunomodulatory ADC payload platform targeting RNA splicing

Pleasanton, CA, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Peak Bio, Inc. ("Peak Bio" or the "Company") (OTC PK: PKBO), is a clinical-stage biopharmaceutical company focused on developing and...
August 31, 2023 09:35 ET | Source: Peak Bio, Inc.

Peak Bio, Inc. Announces Up-listing to OTCQB Market

Pleasanton, CA, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Peak Bio, Inc. ("Peak Bio" or the "Company") (OTC PK: PKBO), is a clinical-stage biopharmaceutical company focused on developing and commercializing...
August 31, 2023 08:00 ET | Source: Peak Bio, Inc.

Peak Bio, Inc., Announces Appointment of Michael Friedman to Board of Directors

Pleasanton, CA, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Peak Bio, Inc. ("Peak Bio" or the "Company") (OTC PK: PKBO), is a clinical-stage biopharmaceutical company focused on developing the next-generation...
August 29, 2023 08:00 ET | Source: Peak Bio, Inc.

Peak Bio, Inc. Announces its Application to Uplist to the OTCQB Venture Market

Pleasanton, CA, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Peak Bio, Inc. ("Peak Bio" or the "Company") (OTC PK: PKBO), is a clinical-stage biopharmaceutical company focused on developing and commercializing...
August 24, 2023 16:05 ET | Source: Peak Bio, Inc.

Peak Bio, Inc. Announces Amendment and Continued Access to Equity Line of up to $100 Million USD via an Accelerated Common Stock Purchase Transaction with White Lion Capital

Pleasanton, CA, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Peak Bio, Inc. ("Peak Bio" or the "Company") (OTC PK: PKBO), is a clinical-stage biopharmaceutical company focused on developing and commercializing...
August 23, 2023 15:50 ET | Source: Peak Bio, Inc.

Peak Bio, Inc. Presents Preclinical Data Highlighting Potential of Differentiated Trop2 PH1 (Novel Payload) ADC in Poster at 2023 AACR Annual Meeting

Pleasanton, CA, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Peak Bio, Inc. ("Peak Bio" or the "Company") (OTC PK: PKBO), is a clinical-stage biopharmaceutical company focused on developing the next-generation...